Content and characteristics of ivermectin in master formulations

Authors

Keywords:

high pressure liquid chromatography, ivermectin, quality control.

Abstract

Introduction: Following the declaration of COVID-19 as a pandemic, the search for treatments intensified. In Peru, ivermectin was proposed as an initial treatment due to its supposed safety, with recommendations for its use to reduce viral load.
Objective: To determine the content and characteristics of ivermectin in compounded formulas.
Methods: Quantitative, cross-sectional descriptive study. Ivermectin drop formulas (6 mg/mL) were analyzed in Lima: 3 from specialized pharmacies (samples A, B, C), 2 from a private health institution (D, E), 1 from a state health institution (F), and 1 commercial product (G). Dosage was performed using high-performance liquid chromatography, and organoleptic characteristics and pH were also measured.
Results: The dosage of commercial ivermectin was 97.5%. The dosages for samples A: 93.2% (5.59 mg/mL), B: 62.8% (3.77 mg/mL), C: 95.8% (5.75 mg/mL), D: 41.7% (2.50 mg/mL), E: 84.0% (5.04 mg/mL), and F: 36.2% (2.17 mg/mL). The pH ranged from 3.02 to 7.10, and the organoleptic characteristics varied across the samples.
Conclusions: Several samples had insufficient concentrations, revealing deficiencies in the quality of ivermectin formulations from specialized pharmacies and public health institutions in Lima.

Downloads

Download data is not yet available.

Author Biographies

Jenny Rosalyn Huerta León, Universidad María Auxiliadora

Docente investigador

Jhonnel Williams Samaniego Joaquin, Universidad María Auxiliadora

Decano de la Facultad de Ciencias de la Salud de la Universidad María Auxiliadora

Gerson Córdova Serrano, Universidad María Auxiliadora

Doecnte investigador

References

1. Organización Mundial de la Salud (OMS). La OMS caracteriza a COVID-19 como una pandemia [Internet]. Ginebra: OMS; 2020. [acceso: 06/08/2020]. Disponible en: https://www.paho.org/hq/index.php?option=com_content&vie-w=article&id=15756:who-characterizes-covid-19-as-a-pandemic&Itemid=1926&lang=es

2. Verdú JR. Expertos de la UA en ivermectina destacan la disponibilidad global del antiparasitario que podría acabar con el Covid-19 [Internet]. Alicante: Universidad de Alicante; 2020. [acceso 06/08/2020]. Disponible en: https://web.ua.es/es/actualidad-universitaria/2020/abril2020/1-12/expertos-de-la-ua-en-ivermectina-destacan-la-disponibilidad-global-del-antiparasitario-que-podria-acabar-con-el-covid-19.html

3. Castañeda E, González A, Grau R, Caballero J. Uso de ivermectina en pacientes con la COVID-19: Una revisión narrativa [Internet]. Rev Cuerpo Med HNAAA. 2020; 13(4): 440-5. DOI: 10.35434/rcmhnaaa.2020.134.780

4. Nastaran B, Motavallihaghi S, Nikfar B, Chaichian S, Momtazi‐Borojeni A. Potential therapeutic effects of ivermectin in covid-19 [Internet]. Experimental Biology and Medicine. 2022 [acceso: 13/05/2023]; 247(15):1388-96. DOI: 10.1177/15353702221099579

5. Gobierno Regional de Cajamarca. Gobierno Regional inicia producción de Ivermectina para tratar a pacientes COVID [Internet]. Cajamarca: Gobierno Regional de Cajamarca; 2020 [acceso: 10/11/2020]. Disponible en: https://www.gob.pe/institucion/regioncajamarca/noticias/188272-gobierno-regional-inicia-produccion-de-ivermectina-para-tratar-a-pacientes-covid

6. Luque J, Pareja A. Seguridad y eficacia de ivermectina en tiempos de COVID-19 [Internet]. Horiz Med. 2021 [acceso:10/01/2023]; 21(1):1331. Disponible en: http://dx.doi.org/10.24265/horizmed.2021.v21n1.10

7. Llahuilla L, Quiñonez L. Propuesta de reglamento peruano que regule los estudios de estabilidad de productos biotecnológicos [Internet]. [Tesis de pregrado]. Lima, Perú: Universidad Nacional Mayor De San Marcos, Facultad de Farmacia y Bioquímica; 2018 [acceso: 10/11/2020]. Disponible en: https://core.ac.uk/download/pdf/323347211.pdf

8. Vázquez S, González L, Dávila M, Crespo C. Determinación del pH como criterio de calidad en la elaboración de fórmulas magistrales orales líquidas [Internet]. Farm Hosp. 2018 [acceso: 10/11/2020]; 42(6): 221-7. Disponible en: http://scielo.isciii.es/pdf/fh/v42n6/es_2171-8695-fh-42-06-221.pdf

9. Rojas P, Castillo E, Rodrigo M. Estudio de Estabilidad Acelerada de cápsulas de Fluoxetina 20 mg [Internet]. 2016 [acceso: 05/04/2023]; 8(1):126-8. Disponible en: https://revistas.uss.edu.pe/index.php/tzh/article/view/338

10. Vázquez S, González L, Dávila M, Crespo C. Determinación del pH como criterio de calidad en la elaboración de fórmulas magistrales orales líquidas [Internet]. Farm Hosp. 2018 [acceso: 07/02/2023]; 42(6): 221-7. DOI: 10.7399/fh.10932

11. Domínguez Granda J B. Manual de metodología de la investigación científica. 3° ed. Chimbote, Perú: Manual de Metodología, Universidad Católica Los Ángeles Chimbote; 2015. [acceso: 22/09/2020]. Disponible en: http://repositorio.uladech.edu.pe/handle/123456789/6404

12. The United States Pharmacopeial Convention. Farmacopea de los Estados Unidos de América USP 38 NF 33. Rockville: The United States Pharmacopeial Convention; 2015. DOI: 10.31003/USPNF_M7808_07_01

13. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Validation of Analytical Procedures: Text and Methodology Q2 (R1) [Internet]. Ginebra: ICH; 2005. [acceso: 10/04/2024]. Disponible en: https://database.ich.org/sites/default/files/ICH_Q2%28R2%2-9_Guideline_2023_1130.pdf

14. Vessman J, Raluca I Stefan, Jacobus F van Staden, Danzer K, Linder W, Thorburn D. International Union of Pure and Applied Chemistry. Selectivity in Analytical Chemistry [Internet]. Pure Appl Chem. 2001 [acceso: 07/02/2023]; 73(8):1381-6. Disponible en: https://publications.iupac.org/pac-2007/2001/pdf/7308x1381.pdf

15. Samaddar A, Grover M, Nag L. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. Front Pharmacol [Internet]. 2020 [acceso: 10/02/2023]; 11:585888. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527880/

Downloads

Published

2024-11-23

How to Cite

1.
Huerta León JR, Samaniego Joaquin JW, Benites Guerrero J, Reyes de la Cruz H, Sánchez Pillaca L, Tito Quispe LM, et al. Content and characteristics of ivermectin in master formulations. Rev Cubana Med Milit [Internet]. 2024 Nov. 23 [cited 2025 Mar. 31];53(4):e024045001. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/45001

Issue

Vol. 53 No. 4 (2024): October - December

Section

Brief Communication

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.